Genentech takes over Regor’s RGT-419B for US$850m upfront
Genentech, the US subsidiary of Swiss pharmaceutical giant Roche AG, has strengthened the company's breast cancer pipeline by pre-licensing the global commercialisation rights to Regor Therapeutics' RGT-419B for US$850m.
With a definitive purchase agreement of Genentech to acquire Chinese Regor Therapeutics Group’s next-generation CDK 4/6 inhibitors including its Phase I candidate RGT-419B for the treatment of breast cancer, the US subsidiary of Swiss Pharma giant Roche AG shows ambitions to attack the current blockbuster medicines Ibrance (Pfizer Inc), Verzenio (Eli Lilly & Company) and Kisqali (Novartis AG).
Under the terms of the agreement, Regor will receive an upfront cash payment of US$850m and is eligible to receive additional, not specified cash payments based on the achievement of certain milestones. While Genentech will be responsible for clinical development, manufacturing and commercialisation worldwide, Regor will manage the two ongoing Phase I trials to their completion: Regor will also advance its other distinct assets, unrelated to this deal, in oncology, metabolic diseases and auto-immunity.
The proposed transaction is expected to close in the fourth quarter of 2024. The closing of the proposed transaction is subject to the satisfaction of customary closing conditions. In Phase I dose escalation studies in advanced breast cancer patients, 67% of which has metastases and who had undergone chemotherapy plus other CDK 4/6 treatments, RGT-419B showed no dose-limiting toxicity.
Sangamo Therapeutics Inc
Maxwell Hamilton - wikipedia.org